李晓晨.肺动脉高压的治疗进展[J].内科急危重症杂志,2024,30(5):385-390
扫码阅读全文
|
| DOI：10.11768/nkjwzzzz.20240501 |
| 中文关键词: 肺动脉高压 治疗 决策 |
| 英文关键词: |
| 基金项目:国家自然科学基金（81973987） |
|
| 摘要点击次数: 335 |
| 全文下载次数: 316 |
| 中文摘要: |
| 摘要 肺动脉高压（PH）是指由多种异源性疾病（病因）和不同发病机制所致肺血管结构或功能改变，引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征，继而发展成右心衰竭甚至死亡。PH是一个重大的全球健康问题，所有年龄段的人群均可发生PH。临床实践中，PH的治疗和管理具有复杂性、异质性、专业性的特点，需要医患共同决策的全方位、整体化、多学科的策略。本文将结合最新国内外指南及高质量临床研究和真实世界数据总结PH的治疗进展。 |
| 英文摘要: |
| Abstract Pulmonary hypertension (PH) is a clinical and pathophysiologic syndrome of elevated pulmonary vascular resistance and pulmonary arterial pressure due to structural or functional changes in the pulmonary vasculature caused by a variety of heterogenic diseases (etiology) and different pathogenic mechanisms,followed by the development of right heart failure or even death.PH is a major global health problem, and it can occur in people of all ages.In clinical practice, the treatment and management of PH is characterized by complexity, heterogeneity, and specialization, and requires an all-encompassing, holistic, and multidisciplinary strategy of shared decision-making between doctors and patients. This article summarizes the advances in the treatment of PH in the light of the latest national and international guidelines and high-quality clinical studies and real-world data. |
|
|
|
|
